Skip to content

For investors & strategic partners

Back a first-in-class microbiome platform with clinical proof.

Microbiome-as-a-Drug across two high-unmet-need tracks — CNS and oncology — built on a 300+ strain library, industrialized FMT 3.0, and AI-native discovery.

300+

Reserved functional strains

5+

World medical records

10,000+

FMT & assays performed

The opportunity

Why now

The microbiome is moving from supplements to a programmable drug class. We pair an industrialized FMT 3.0 process (P2 + GMP) with a proprietary strain library and AI-native discovery to pursue indications where standard care leaves large gaps — depression & mood disorders, and immune-checkpoint sensitization in “cold” tumors.

aFMT-102 CNS

Major depressive disorder & mood disorders

Live biotherapeutic (Bifidobacterium longum strain) / FMT 3.0 · Preclinical

Next: IND-enabling studies

ICI-sensitizing FMT (CRC) Onco

pMMR / MSS colorectal cancer (ICI-refractory)

FMT 3.0 + immune-checkpoint inhibitor combination · Discovery

Next: Investigator-led cohort expansion

Qualifications

Full qualifications & compliance →

Ways to partner

Equity investment

Strategic and financial investors backing a first-in-class microbiome platform.

Licensing & co-development

Program-level partnerships across CNS and oncology assets.

Clinical & manufacturing

Hospital collaborations and FMT 3.0 supply via our P2 + GMP facility.

Let’s talk

Request the investor brief.

A gated data room is on the roadmap; for now we share materials on request. Tell us who you are and what stage of conversation you’re ready for.

Form integration pending.

Configure site.contact.formspreeId in src/data/site.ts with your Formspree form ID to enable this form (free at formspree.io).

Prefer to browse first? Key statistics · Evidence · FAQ